Thermo Fisher Scientific expands diagnostics portfolio to support full qPCR assay development and testing workflow
_256_384.jpg)
Both parties are expected to invest a total of US $ 1 million to establish the brand
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
The new devices company will scale up its teams to create a world-class R&D centre for medical devices in India
It tests for the presence or absence of ribonucleic acid (RNA) of Dengue (Type 1, 2 4) in serum or plasma from patients suspected of dengue viral infection.
First diagnostic centre to open in Mohali on August 31
This year, the company plans to set up more than 200 labs and 3000 collection centres across the world and has ended FY 21 with a revenue of Rs 800 crores
The aim is to create new genomics solutions that could combat cancer and advance market access
Price band in the range of Rs 933 to Rs 954
Investment demonstrates confidence in America’s commitment to science and innovation
Subscribe To Our Newsletter & Stay Updated
